Synergistic Antitumor Activity of Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA 2+1 T Cell Engager (TCE), and Celmod Agents in Multiple Myeloma (MM) Preclinical Models

被引：14
|
作者：
Paiva, Bruno [1 ]
Gaffney, Bonny [2 ]
Burnett, Kelven [2 ]
Castiglioni, Paola [2 ]
Angelo, Michael [2 ]
Pierce, Daniel W. [3 ]
Boss, Isaac W. [4 ]
机构：
[1] Clin Univ Navarra, Inst Invest Sanitaria Navarra IDISNA, Ctr Invest Med Aplicada CIMA, Canc Ctr Univ Navarra CCUN, Navarra, Spain
[2] Bristol Myers Squibb Co, San Diego, CA USA
[3] Bristol Myers Squibb Co, San Francisco, CA USA
[4] Bristol Myers Squibb Co, Translat Res, Seattle, WA USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-157987
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7054 / 7055
页数：2
相关论文
共 7 条
  • [1] Synergistic antitumor activity of the BCMA 2+1 T-cell engager (TCE) alnuctamab (ALNUC; BMS-986349; CC-93269) and CELMoD agents in multiple myeloma (MM) preclinical models
    Paiva, Bruno
    Gaffney, Bonny
    Burnett, Kelven
    Castiglioni, Paola
    La Motte-Mohs, Ross
    Angelo, Michael
    Pierce, Daniel
    Boss, Isaac
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S46 - S47
  • [2] Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
    Wong, Sandy W.
    Bar, Noffar
    Paris, Laura
    Hofmeister, Craig C.
    Hansson, Markus
    Santoro, Armando
    Mateos, Maria-Victoria
    Rodriguez-Otero, Paula
    Lund, Johan
    Encinas, Cristina
    Yee, Andrew J.
    Oriol, Albert
    Cerchione, Claudio
    de la Rubia, Javier
    Ferstl, Barbara
    Carlson, Kristina
    Ribas, Paz
    Bermudez, Arancha
    Boss, Isaac W.
    Gaudy, Allison
    Li, Shaoyi
    Hsu, Kevin
    Godwin, Colin D.
    Burgess, Michael R.
    San-Miguel, Jesus
    Costa, Luciano J.
    BLOOD, 2022, 140
  • [3] Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA x CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study
    Costa, Luciano
    Bar, Noffar
    Mateos, Maria-Victoria
    Ribas, Paz
    Hansson, Markus
    Paris, Laura
    Hofmeister, Craig
    Rodriguez-Otero, Paula
    Bermudez, Maria Aranzazu
    Santoro, Armando
    Yee, Andrew
    Creignou, Maria
    Encinas, Cristina
    Cerchione, Claudio
    de la Rubia, Javier
    Oriol, Albert
    Ferstl, Barbara
    Besemer, Britta
    Chen, Jinjie
    Boss, Isaac
    Gaudy, Allison
    Hsu, Kevin
    Godwin, Colin
    San-Miguel, Jesus
    Wong, Sandy
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S52 - S53
  • [4] Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B- Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study
    Bar, Noffar
    Victoria Mateos, Maria
    Ribas, Paz
    Hansson, Markus
    Paris, Laura
    Hofmeister, Craig C.
    Rodriguez Otero, Paula
    Aranzazu Bermudez, Maria
    Martin, Thomas
    Santoro, Armando
    Yee, Andrew J.
    Creignou, Maria
    Encinas Rodriguez, Cristina
    Cerchione, Claudio
    De La Rubia, Javier
    Oriol, Albert
    Waibel, Heidi
    Besemer, Britta
    Thompson, Ethan
    Kiesel, Brian
    Chen, Jinjie
    Chung, Alexander
    Boss, Isaac W.
    Gaudy, Allison
    Li, Shaoyi
    Hsu, Kevin
    Godwin, Colin
    Burgess, Michael R.
    San-Miguel, Jesus
    Costa, Luciano
    BLOOD, 2023, 142
  • [5] Soluble Factors Correlated with High-Grade Cytokine Release Syndrome (CRS): A Comparison of Subcutaneous (SC) Versus Intravenous (IV) Delivery of Alnuctamab (ALNUC; BMS-986349; CC-93269) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
    Boss, Isaac W.
    Thompson, Ethan
    Gaudy, Allison M.
    Vu, Minh Diem
    Godwin, Colin D.
    Burgess, Michael R.
    Wong, Sandy W.
    Costa, Luciano J.
    BLOOD, 2022, 140 : 7116 - 7117
  • [6] Targeting B-Cell Maturation Antigen (BCMA) with CC-93269, a 2+1 T Cell Engager, Elicits Significant Apoptosis in Diffuse Large B-Cell Lymphoma Preclinical Models
    Hagner, Patrick R.
    Waldman, Michelle
    Gray, Falon D.
    Yura, Renee
    Hersey, Sarah
    Chan, Henry
    Zhang, Mingjun
    Boss, Isaac
    Gandhi, Anita K.
    BLOOD, 2019, 134
  • [7] First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial
    Costa, Luciano J.
    Wong, Sandy W.
    Bermudez, Arancha
    de la Rubia, Javier
    Mateos, Maria-Victoria
    Ocio, Enrique M.
    Rodriguez-Otero, Paula
    San-Miguel, Jesus
    Li, Shaoyi
    Sarmiento, Rafael
    Lardelli, Pilar
    Gaudy, Allison
    Boss, Isaac
    Kelly, Lisa M.
    Burgess, Michael R.
    Hege, Kristen
    Bensinger, William I.
    BLOOD, 2019, 134
1